Drugs / thymoglobulin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03456817 | Jul 2020 → May 2025 | graft versus host disease | AHS Cancer Control Alberta | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | thymoglobulin | “ATG (thymoglobulin)” NCT03456817 ↗ |
| Known as | ATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03456817 ↗ |
| Route | Intravenous | “The high dose ATG will be given into patient's vein via central venous catheter.” NCT03456817 ↗ |